Abstract 3629
Background
Programmed death-1 inhibitors (PD-1i) have been approved in the treatment of patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who progressed on or after platinum-containing regimens. More recently, it has been shown that pembrolizumab was superior to the standard EXTREME regimen in first line setting in pts with R/M SCCHN with CPS > 20% and 1% in term of overall survival (OS). We aim in this study to compare the efficacy of immune checkpoint inhibitors (ICI) used as first versus second line in R/M SCCHN to define the best treatment strategy.
Methods
A retrospective study was conducted at 4 French university hospitals. Eligibility criteria were pts treated with ICI for R/M SCCHN as first or second line treatment only and for whom efficacy data were available between September 2014 and March 2019. Clinical and radiological data and outcome were collected from review of medical records.
Results
One hundred ninety two pts were included in this study: 57 pts (30%) received ICI as first line treatment (G1) and 135 pts (70%) as second line setting (G2). Median age at the beginning of ICI was 63 years (range 25-86). All pts were in clinical trials. In G1, ICI was given as monotherapy in 23% of pts and in 66% of pts in G2. The objective response rate (ORR) to ICI in G1 was 17.5% and 17.9% in G2 (p = 0.004). The median duration of response to ICI in G1 was 7.3 months compared to 15.2 months in G2 (p = 0.04). The median progression free survival in G1 was 3.3 months versus 2.7 months in G2 (p = 0.7). The mOS from the beginning of ICI was 12.2 months in G1 versus 11.6 months in G2 (p = 0.7). The mOS from the diagnosis of advanced disease was 15.9 months in G1 versus 22.1 months in G2 (p = 0.11) after a median follow-up of 28.5 months. In G1 38 pts (67%) and 73 pts (53%) in G2 received salvage chemotherapy (SCT) after progression on ICI. The ORR to SCT was 44% in G1 and 34% in G2.
Conclusions
ICI given as second line treatment were associated with similar OS but significant prolonged duration of response. We showed a trend to better OS in the cohort of pts who received ICI in second line setting (22 months).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5579 - Quality of informed consent in clinical trials patients
Presenter: Gianluca Catania
Session: Poster Display session 3
Resources:
Abstract
5147 - Patient's rights: Where do we stand?
Presenter: Maja Kozuh
Session: Poster Display session 3
Resources:
Abstract
1279 - The oncology nurse coordinator’s role in a digestive oncology department: Impact on patient and hospital
Presenter: Fouad Awada
Session: Poster Display session 3
Resources:
Abstract
1670 - Nursing model for a breast cancer unit at the Catalan Institute of Oncology
Presenter: Ana Rodriguez-ortega
Session: Poster Display session 3
Resources:
Abstract
3936 - Role of cancer nurse in the prevention and control of acute deterioration for oncohematologic patient
Presenter: Raquel Azor Portolés
Session: Poster Display session 3
Resources:
Abstract
2789 - Standardized nursing care in the department of radiotherapy of a network of cancer centres
Presenter: José Delgado
Session: Poster Display session 3
Resources:
Abstract
4482 - Exploring anxiety, depression and quality of life of ambulatory cancer patients during chemotherapy.
Presenter: Theodoula Adamakidou
Session: Poster Display session 3
Resources:
Abstract
3075 - Implementing a Cancer Survivorship Program for Individuals with Recurrent Breast Cancer
Presenter: Darcy Burbage
Session: Poster Display session 3
Resources:
Abstract
3869 - The perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage The perceptions of parents/guardians regarding their child/adolescents experience of reflexology or non-specific foot massage
Presenter: Patricia Fox
Session: Poster Display session 3
Resources:
Abstract
4064 - Quality of life in survivors of adult haematological malignancies
Presenter: Anita Immanuel
Session: Poster Display session 3
Resources:
Abstract